The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 1.80
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (27.778%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.15
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Dealings

23 Jul 2009 16:17

RNS Number : 2020W
Immupharma PLC
23 July 2009
 



For Immediate Release

23 July 2009

ImmuPharma PLC

Directors' Dealings

Institutions increase stake

 

ImmuPharma PLC ('ImmuPharma' or the 'Company') (LSE:IMM) announces that a number of existing and new blue-chip institutional investors have purchased shares from Richard Warr and the Trusts of Richard Warr and Dimitri Dimitriou, who are two of ImmuPharma's founders and Directors.  A total of 12.5 million ordinary shares (16.1% of the issued share capital) of 10 pence each in the Company, were placed by Noble & Company Limited at a price of 86 pence per share to institutional investors on 23 July 2009. Panmure Gordon is the NOMAD and Corporate Broker to the Company. 

 

Following the disposal, the current holdings directly or through Trust are:

Ordinary Shares Sold

Ordinary Shares Retained

Percentage  of shares in issue

Richard Warr (1)

6,250,000

3,528,968

4.6%

Dimitri Dimitriou (2)

6,250,000

3,528,969

4.6%

Dr Zimmer & Family

0

23,056,602

29.8%

 

(1)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Warr family has a beneficial interest and shares held directly by Richard Warr

 

(2)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Dimitriou family has a beneficial interest. 

 

Richard Warr, ImmuPharma's Chairman said: "We are delighted with the support received from our existing investors and the demand from new investors including M&G Investments.  The allocation of these shares further increases ImmuPharma's free float with the aim of improving overall liquidity."

 

For further information please contact: 

ImmuPharma PLC

+44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer 

Richard Warr, Chairman

Panmure Gordon

+44 151 243 0963

Andrew Burnett/ Rakesh Sharma 

Noble & Company Limited

+44 20 7763 2335

John Millar

Buchanan Communications

+44 20 7466 5000

Lisa Baderoon 

Rebecca Skye Dietrich

More information on the Company can be found at www.immupharma.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSELFIDSUSEFW
Date   Source Headline
3rd May 20247:00 amRNSHolding(s) in Company
24th Apr 20247:12 amRNSIMMUPHARMA AT BIO-EQUITY 2024 12-14 May
19th Apr 20247:00 amRNSGrant of Share Options
2nd Apr 20247:03 amRNSNew intellectual property strategy initiated
25th Mar 20247:25 amRNSIncanthera provides Comm'l Update/Revenue F'casts
19th Mar 20247:00 amRNSGrant of Share Options
14th Mar 20247:00 amRNSIMMUPHARMA AT BIO-EUROPE SPRING 2024
6th Mar 20247:00 amRNSFinancial, Business and Portfolio Develop't Update
28th Dec 20231:35 pmRNSHolding(s) in Company
19th Dec 20232:50 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNSSimbec-Orion appointed as CRO
18th Dec 20237:15 amRNSIncanthera - Comm'l Skincare Deal/£1M Fundraise
13th Sep 20233:47 pmRNSHolding(s) in Company
7th Sep 20237:00 amRNSResult of Retail Offer and Director Shareholding
31st Aug 20237:02 amRNSWRAP Retail Offer for up to £0.5m
31st Aug 20237:01 amRNSSubscription to raise £1.35m; Sharing Agr, RPT
31st Aug 20237:00 amRNSInterim results
21st Aug 20237:00 amRNSExtension of warrants in Incanthera plc
11th Aug 202312:04 pmRNSDirectorate Change
30th Jun 20231:12 pmRNSResult of AGM
19th Jun 20237:00 amRNSLupuzor Update
6th Jun 20237:00 amRNSIMM RNS Posting of RA and Notice of AGM 30 June 23
18th May 20237:00 amRNSPositive Pre-IND meeting with FDA
11th May 20237:00 amRNSFinal Results
10th May 20231:56 pmRNSHolding(s) in Company
19th Apr 20237:00 amRNSLupozor Update - FDA confirms Type-C meeting date
12th Apr 20237:00 amRNSCIDP P140 Clinical Program Update
27th Mar 20237:00 amRNSLupuzor™ Update
9th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20237:00 amRNSCollaboration with Orano on ImmuPharma Peptide
6th Feb 20237:00 amRNSLupuzor™ Update
27th Jan 20234:25 pmRNSTR-1: Notification of major holdings
4th Jan 20235:26 pmRNSTR-1: Notification of major holdings
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn
4th Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20234:58 pmRNSTR-1: Notification of major holdings
22nd Dec 20227:55 amRNSGrant of Options
22nd Dec 20227:00 amRNSEnd of Year Update
22nd Nov 20223:15 pmRNSHolding(s) in Company
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
11th Nov 20227:31 amRNSLupuzor Update
11th Oct 20224:40 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
7th Oct 20224:44 pmRNSCompany Secretary Change
6th Oct 20225:17 pmRNSHolding(s) in Company
30th Sep 20227:30 amRNSLupuzor Update
30th Sep 20227:00 amRNSInterim Results or the 6mths Ended 30 June 2022
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.